“We are pleased to welcome Darcy and Emily to Fortis,” said Dave King, CEO of Fortis Life Sciences. “Their exceptional leadership, strategic insight, and extensive industry expertise will further ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain ...

Brenner, who has worked in the FDA’s Center for Devices and Radiological Health, will lead the agency until a permanent ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

The rescinded Biden-era orders include actions to boost the Affordable Care Act exchanges, coordinate the government’s ...